Literature DB >> 6542338

Prostaglandin E1 in suspected ductus dependent cardiac malformation.

K A Hallidie-Smith.   

Abstract

Fifty two sick neonates with major duct dependent cardiac defects were given short term intravenous infusions of prostaglandin E1 (alprostadil) in doses varying between 0.005 and 0.1 micrograms/kg/minute. The object of the study was to try to achieve an effective but safe regiment that could be instituted as soon as such a diagnosis was suspected. Effective clinical improvement was achieved at each dosage but the incidence of side effects seemed to be dose related, and no serious side effects were noted at a dosage of 0.005 to 0.01 micrograms/kg/minute. It is recommended that a low dosage regimen be started before transfer to a paediatric cardiac centre.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6542338      PMCID: PMC1628837          DOI: 10.1136/adc.59.11.1020

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  22 in total

1.  Effect of orally administered prostaglandin E1 on gastric secretion and gastrointestinal motility in man.

Authors:  E W Horton; I H Main; C J Thompson; P M Wright
Journal:  Gut       Date:  1968-12       Impact factor: 23.059

2.  Circulatory and respiratory effects of different doses of prostaglandin E1 in man.

Authors:  L A Carlson; L G Ekelund; L Orö
Journal:  Acta Physiol Scand       Date:  1969 Jan-Feb

3.  Neurological and electroencephalographic changes in newborns treated with prostaglandins E1 and E2.

Authors:  R Fariello; P M Olley; F Coceani
Journal:  Prostaglandins       Date:  1977-05

4.  Studies on the effects of prostaglandins E1, E2, A1, and A2 on the dustus arteriosus of swine in vivo using cineangiography.

Authors:  M B Starling; J M Neutze; R L Elliott; R B Elliott
Journal:  Prostaglandins       Date:  1976-09

5.  E-type prostaglandins: a new emergency therapy for certain cyanotic congenital heart malformations.

Authors:  P M Olley; F Coceani; E Bodach
Journal:  Circulation       Date:  1976-04       Impact factor: 29.690

6.  The prostaglandin challenge. Test to unmask obstructed total anomalous pulmonary venous connections in asplenia syndrome.

Authors:  R M Freedom; P M Olley; F Coceani; R D Rowe
Journal:  Br Heart J       Date:  1978-01

7.  Administration of prostaglandin E1 in neonates with critical congenital cardiac defects.

Authors:  A B Lewis; M Takahashi; P R Lurie
Journal:  J Pediatr       Date:  1978-09       Impact factor: 4.406

8.  Dilatation of the ductus arteriosus by prostaglandin E1 in aortic arch abnormalities.

Authors:  M A Heymann; W Berman; A M Rudolph; V Whitman
Journal:  Circulation       Date:  1979-01       Impact factor: 29.690

9.  Ductus arteriosus responses to prostaglandin E1 at high and low oxygen concentrations.

Authors:  R I Clyman; M A Heymann; A M Rudolph
Journal:  Prostaglandins       Date:  1977-02

10.  Palliation of cyanotic congenital heart disease in infancy with E-type prostaglandins.

Authors:  J M Neutze; M B Starling; R B Elliott; B G Barratt-Boyes
Journal:  Circulation       Date:  1977-02       Impact factor: 29.690

View more
  7 in total

Review 1.  PROSTAGLANDINS IN CONGENITAL HEART DISEASE.

Authors:  M Sharma; M Sasikumar; S D Karloopia; B N Shahi
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 2.  The pharmacological treatment of patent ductus arteriosus. A review of the evidence.

Authors:  R J Barst; W M Gersony
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

3.  Caffeine prevents prostaglandin E1-induced disturbances in respiratory control in neonatal rats: implications for infants with critical congenital heart disease.

Authors:  L J Mitchell; C A Mayer; A Mayer; J M Di Fiore; S L Shein; T M Raffay; P M MacFarlane
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-06-24       Impact factor: 3.619

4.  Evaluation of oral and low dose intravenous prostaglandin E2 in management of ductus dependent congenital heart disease.

Authors:  E D Silove; D G Roberts; J V de Giovanni
Journal:  Arch Dis Child       Date:  1985-11       Impact factor: 3.791

5.  Evaluation of low dose prostaglandin E1 treatment for ductus dependent congenital heart disease.

Authors:  H H Kramer; M Sommer; S Rammos; O Krogmann
Journal:  Eur J Pediatr       Date:  1995-09       Impact factor: 3.183

Review 6.  Mechanistic actions of oxygen and methylxanthines on respiratory neural control and for the treatment of neonatal apnea.

Authors:  Lisa Mitchell; Peter M MacFarlane
Journal:  Respir Physiol Neurobiol       Date:  2019-10-15       Impact factor: 1.931

Review 7.  Prostaglandin E1 for maintaining ductal patency in neonates with ductal-dependent cardiac lesions.

Authors:  Smita Akkinapally; Shilpa G Hundalani; Madhulika Kulkarni; Caraciolo J Fernandes; Antonio G Cabrera; Binoy Shivanna; Mohan Pammi
Journal:  Cochrane Database Syst Rev       Date:  2018-02-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.